Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial).

[1]  D. Fitzmaurice,et al.  Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. , 2020, Journal of the American College of Cardiology.

[2]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[3]  M. Böhm,et al.  Adherence to Antihypertensive Drugs Assessed by Hyphenated High‐Resolution Mass Spectrometry Analysis of Oral Fluids , 2020, Journal of the American Heart Association.

[4]  S. Yusuf,et al.  Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. , 2020, European heart journal.

[5]  G. Lip,et al.  Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme. , 2019, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[6]  K. Alexander,et al.  Deprescribing in Older Adults With Cardiovascular Disease. , 2019, Journal of the American College of Cardiology.

[7]  Deepak L. Bhatt,et al.  Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). , 2018, European heart journal.

[8]  D. Xavier,et al.  Polypharmacy and effects of apixaban versus warfarin in patients with atrial fibrillation: post hoc analysis of the ARISTOTLE trial , 2016, British Medical Journal.

[9]  P. Ponikowski,et al.  Non‐adherence to ivabradine and placebo and outcomes in chronic heart failure: an analysis from SHIFT , 2016, European journal of heart failure.

[10]  G. Lip,et al.  Adherence to antithrombotic therapy guidelines improves mortality among elderly patients with atrial fibrillation: insights from the REPOSI study , 2016, Clinical Research in Cardiology.

[11]  J. Beyer-Westendorf,et al.  Real-world persistence and adherence to oral anticoagulation for stroke risk reduction in patients with atrial fibrillation. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.

[12]  J. Beyer-Westendorf,et al.  Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation , 2015, Thrombosis and Haemostasis.

[13]  M. Molokhia,et al.  Efficacy and Harms of Direct Oral Anticoagulants in the Elderly for Stroke Prevention in Atrial Fibrillation and Secondary Prevention of Venous Thromboembolism: Systematic Review and Meta-Analysis , 2015, Circulation.

[14]  G. Lip,et al.  New Oral Anticoagulants in Elderly Adults: Evidence from a Meta‐Analysis of Randomized Trials , 2014, Journal of the American Geriatrics Society.

[15]  A. Nobili,et al.  Medication Non-Adherence Among Elderly Patients Newly Discharged and Receiving Polypharmacy , 2014, Drugs & Aging.

[16]  Michael Böhm,et al.  Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease. , 2013, American heart journal.

[17]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[18]  P Michael Ho,et al.  Medication Adherence: Its Importance in Cardiovascular Outcomes , 2009, Circulation.